美力敦宣布启动IPO路演-动脉网

MiniMed announces launch of IPO roadshow

美敦力等信源发布 2026-02-24 21:32



可切换为仅中文







GALWAY

戈尔韦

，

Ireland

爱尔兰

，

Feb. 24, 2026

2026年2月24日

PRNewswire

美通社

/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE: MDT), today announced that it has launched a roadshow for the initial public offering (IPO) of 28,000,000 shares of its common stock. The proposed offering is part of Medtronic's previously announced plan to separate its Diabetes business into an independent public company..

/-- MiniMed集团有限公司（MiniMed），美敦力公司（Medtronic）的子公司（纽约证券交易所代码：MDT），今天宣布已为其28,000,000股普通股的首次公开募股（IPO）启动了路演。此次拟议的发行是美敦力先前宣布的计划的一部分，旨在将其糖尿病业务分拆为一家独立的上市公司。

The IPO price is currently expected to be between

IPO价格目前预计将在

$25.00

25.00美元

and

和

$28.00

28.00美元

per share. The underwriters will also be granted a 30-day option to purchase up to an additional 4,200,000 shares at the IPO price, less underwriting discounts and commissions. MiniMed expects to list its common stock on the Nasdaq Global Select Market (Nasdaq) under the symbol 'MMED.'

每股。承销商还将获得一个30天的期权，可以按首次公开募股价格（扣除承销折扣和佣金后）额外购买最多4,200,000股。MiniMed预计将其普通股在纳斯达克全球精选市场（Nasdaq）上市，股票代码为“MMED”。

Upon completion of the IPO, Medtronic will hold approximately 90.03% of MiniMed (or 88.70% if the underwriters exercise their over-allotment option in full). MiniMed intends to use a portion of the net proceeds from this offering for general corporate purposes. The remainder, if any, will be used to repay intercompany debt owed to Medtronic and as additional consideration to Medtronic for certain assets transferred to MiniMed in the separation. .

首次公开募股完成后，美敦力将持有 MiniMed 约 90.03% 的股份（如果承销商全额行使超额配股权，则为 88.70%）。MiniMed 打算将此次发行的净收益的一部分用于一般公司用途。剩余部分（如有）将用于偿还欠美敦力的公司间债务，并作为某些资产转让给 MiniMed 的分离交易中美敦力的额外对价。

A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

一份关于表格S-1的注册声明，涉及这些证券，已提交给美国证券交易委员会（SEC），但尚未生效。在注册声明生效之前，这些证券不得出售，也不得接受购买要约。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约或购买要约的征求，也不得在任何州或司法管辖区进行此类证券的销售，如果在该州或司法管辖区，此类要约、征求或销售在未根据其证券法进行注册或资格认证前属违法。

Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. References to Medtronic plc and MiniMed Group, Inc., herein may refer to their subsidiaries, respectively..

任何证券的要约、招揽、购买要约或销售，都将根据经修订的《1933年证券法》的注册要求进行。文中提及的美敦力公司（Medtronic plc）和MiniMed集团有限公司（MiniMed Group, Inc.）可能分别指其子公司。

Goldman Sachs & Co. LLC, BofA Securities, Citigroup and Morgan Stanley are acting as the active bookrunners for the proposed offering. Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI and

高盛有限责任公司、美国银行证券、花旗集团和摩根士丹利正在担任此次拟议发行的积极账簿管理人。巴克莱银行、德意志银行证券、瑞穗金融、富国银行证券、Evercore ISI以及

Piper Sandler

派珀·桑德勒

& Co. are also acting as joint book running managers and BTIG and

公司还担任联合账簿管理人，BTIG和

William Blair

威廉·布莱尔

& Company, L.L.C. are acting as co-managers. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the proposed IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street,

公司和L.L.C.担任联席经理。拟议的发行将仅通过招股说明书进行。在可行时，有关拟议首次公开募股的初步招股说明书副本可从高盛集团有限责任公司获取，地址：200 West Street，收件人：招股说明书部门。

New York, NY

纽约，纽约州

10282, by telephone at +1-866-471-2526, by facsimile at +1-212-902-9316 or by email at

10282，电话：+1-866-471-2526，传真：+1-212-902-9316，或电子邮件：

prospectus-ny@ny.email.gs.com

招股说明书-纽约@纽约.电子邮件.高盛.com

; BofA Securities, NC1-022-02-25, 201 North Tryon Street,

; 美银证券，NC1-022-02-25，北特里恩街201号，

Charlotte, NC

北卡罗来纳州夏洛特

28255-0001, Attention: Prospectus Department, by email at

28255-0001，致：招股说明书部，电子邮件：

dg.prospectus_requests@bofa.com

; Citigroup, c/o Broadridge Financial Services, 1155 Long Island Avenue,

; 花旗集团，转交Broadridge金融服务公司，长岛大道1155号，

Edgewood, NY

纽约州埃奇伍德

11717, telephone at +1-800-831-9146; and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor,

11717，电话：+1-800-831-9146；以及摩根士丹利公司，致：招股说明书部，地址：180 Varick Street，2楼，

New York, NY

纽约，纽约州

10014 or by email at

10014 或通过电子邮件

prospectus@morganstanley.com

招股说明书@摩根士丹利.com

。

About MiniMed

关于 MiniMed

MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service.

MiniMed是胰岛素输送领域的全球领导者，不断推进支持80多个国家糖尿病患者的治疗方案。我们全栈式的集成生态系统，包括胰岛素输送系统、连续血糖监测仪（CGMs）、算法以及易于使用的应用程序体验，旨在无缝协作，并由贴心的全方位服务提供支持。

For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes..

四十多年来，我们通过预测需求、减轻负担并帮助糖尿病患者更轻松地生活，开创了人们可以信赖的疗法。我们的使命是让糖尿病患者的每一天都过得更好。

About Medtronic

美敦力公司简介

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in

大胆思考。更大胆的行动。我们是美敦力。美敦力公司，总部位于

Galway

戈尔韦

，

Ireland

爱尔兰

, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

是全球领先的医疗技术公司，大胆攻克人类面临的最棘手的健康问题，寻找并提供解决方案。我们的使命——减轻病痛、恢复健康、延长生命——团结了遍布150多个国家的95,000多名充满热情的员工。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们多样化的知识、无尽的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary..

我们赋能以洞察力为驱动的护理、以人为本的体验以及为我们的世界带来更好的结果，对我们有更多期待吧。在我们所做的每一件事中，我们都在创造非凡。

Cautions Regarding Forward-Looking Statements

关于前瞻性陈述的注意事项

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to Medtronic's ability to satisfy the necessary conditions to consummate the separation of its Diabetes business on a timely basis or at all, Medtronic's ability to successfully separate its Diabetes business and realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders), MiniMed's ability to succeed as a standalone publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S.

本新闻稿包含1995年《私人证券诉讼改革法案》意义下的前瞻性声明，这些声明受风险和不确定性的影响，包括美敦力能否及时或根本满足完成其糖尿病业务分拆的必要条件、美敦力能否成功分拆其糖尿病业务并实现预期的分拆利益（包括以通常对股东免税的方式完成交易）、MiniMed作为一家独立公开上市公司的成功能力、竞争因素、医疗产品开发、制造、营销和销售中固有的困难与延迟、政府监管、地缘政治冲突、全球贸易政策的变化、总体经济状况，以及其他公司定期报告中描述的风险和不确定性，这些报告已提交给美国证券交易委员会。

Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'looking ahead,' 'may,' 'plan,' 'possible,' 'potential,' 'project,' 'should,' 'going to,' 'will,' and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology.

证券交易委员会，包括公司最近的年度报告Form 10-K。在某些情况下，您可以通过前瞻性词语或表达来识别这些陈述，例如“预期”、“相信”、“可能”、“估计”、“预计”、“预测”、“打算”、“展望未来”、“或许”、“计划”、“可能”、“潜力”、“预计”、“应该”、“将要”、“将会”，以及类似的词语或表达、这些词语或表达的否定形式或复数形式，以及其他类似的术语。

Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances. While a split-off is the company's current preferred separation structure, a final deci.

实际结果可能与预期结果有重大差异。美敦力不承担更新其前瞻性声明或本新闻稿中包含的任何信息的责任，包括反映未来事件或情况。虽然分拆是公司目前首选的分离结构，但最终决定尚未做出。

MiniMed Contacts

MiniMed 联系人

Janet Cho

珍妮特·赵

Public Relations

公共关系

+1-818-403-7028

Ryan Weispfenning

瑞安·魏斯芬宁

Investor Relations

投资者关系